CLINICAL TRIALS AND OBSERVATIONS Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
نویسندگان
چکیده
1Assistance Publique-Hôpitaux de Paris, Hôpital Avicenne, Service d’Hématologie Clinique and Paris 13 University, Bobigny; 2Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Unité de Biologie Cellulaire, Paris; 3Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, DBIM, Paris; 4CHU Dupuytren, Service d’Hematologie, Limoges; 5CHRU de Lille, Hopital Huriez, Service des Maladies du Sang, Lille; 6Service d’Hématologie, CHU Purpan, Toulouse; 7Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisiere, Service d’Hématologie, Paris; and 8Inserm U656 and Assistance Publique-Hôpitaux de Paris, Service de Biochimie Hormonale et Génétique, Hôpital Bichat and Paris 7 University, Paris, France
منابع مشابه
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Result of high-dose imatinib mesylate in patients with Philadelphia chromosome–positive chronic myeloid leukemia after failure of interferon-
Imatinib at 400 mg daily is effective in chronic-phase chronic myeloid leukemia (CML) after interferon failure, although only a few patients achieve a molecular remission. We investigated whether higher doses of imatinib may be more effective. Thirty-six patients with chronicphase CML after failure on interferonwere treated with 400 mg imatinib twice daily. Median time from diagnosis was 25 mon...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study
Patients with chronic myeloproliferative neoplasms, including essential thrombocythemia (ET), polycythemia vera (PV), and chronic myeloid leukemia (CML), are at increased risk of new hematologic malignancies, but their risk of nonhematologic malignancies remains unknown. In the present study, we assessed the risk of both types of malignancies after an ET, PV, or CML diagnosis. We linked 2 popul...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Clinical profile of homozygous JAK2 617V F mutation in patients with polycythemia vera or essential thrombocythemia
Alessandro M. Vannucchi,1 Elisabetta Antonioli,1 Paola Guglielmelli,1 Alessandro Rambaldi,2 Giovanni Barosi,3 Roberto Marchioli,4 Rosa Maria Marfisi,4 Guido Finazzi,2 Vittoria Guerini,2 Fabrizio Fabris,5 Maria Luigia Randi,5 Valerio De Stefano,6 Sabrina Caberlon,7 Agostino Tafuri,8 Marco Ruggeri,9 Giorgina Specchia,10 Vincenzo Liso,10 Edoardo Rossi,11 Enrico Pogliani,12 Luigi Gugliotta,13 Alber...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma
Thirty-six patients with AIDS-associated Kaposi sarcoma (KS) requiring chemotherapy were treated for six 3-week cycles of pegylated liposomal doxorubicin (20 mg/m2) plus interleukin-12 (IL-12; 300 ng/kg subcutaneously twice weekly), followed by 500 ng/kg subcutaneous IL-12 twice weekly for up to 3 years. All received highly active antiretroviral therapy (HAART). Twenty-two had poor-prognosis KS...
متن کاملp53 as a target in myeloproliferative neoplasms
The Philadelphia chromosome negative myeloproliferative neoplasms (MPN) originate at the level of the pluripotent hematopoietic stem cell (HSC). JAK2V617F is present in virtually all patients with polycythemia vera (PV) as well as 50-60% of patients with primary myelofibrosis (PMF) and essential thrombocythemia (ET) [1]. Recently, Nakatake and coworkers demonstrated that JAK2V617F alters p53 re...
متن کامل